Pharmacists in Smoking Cessation

NEWS
Eileen Byrne appointed
Managing Director of
Clanwilliam Health
Clanwilliam Group has appointed Eileen Byrne as Managing
Director of its Clanwilliam Health division.
Howard Beggs, CEO of Clanwilliam Group, said Eileen was
well-placed to chart the future direction of Clanwilliam Health.
“Eileen has a vision for the difference technology can make
to healthcare delivery in Ireland. As Managing Director of
Clanwilliam Health, she leads a team of over 150 personnel
in Ireland and the UK that are committed to innovation
and constantly enhancing our offering to pharmacy and GP
customers. I am delighted that she has agreed to take on this
position and look forward to continuing to work with her as
we harness the benefits
of digital advances to
support our customers,”
said Mr Beggs.
Eileen was previously
Director of Customer
Services at Clanwilliam
Group and has been
involved with the
business for the past two
decades, having held
senior roles in training
and implementation
previously.
New CEO takes the
helm at Muscular
Dystrophy Ireland
Muscular Dystrophy Ireland (MDI), the national charity
supporting people with muscular dystrophy and their families
across Ireland, is delighted to announce the appointment of its
new Chief Executive Officer, Mr Richard Lodge.
Mr Lodge was most recently the Network Manager at St Luke’s
Oncology Radiation Network, which operates from St Luke’s
Hospital and St Luke’s Radiation Oncology Units in St James’s
and Beaumont Hospitals in Dublin. Mr Lodge has spent the past
10 years with that organisation, having previously been the CEO
of St Luke’s Hospital.
Mr Lodge holds an MBA from Middlesex University and a
Master’s degree in Transfusion Medicine from Westminster
University. He is a Fellow of the Institute of Biomedical Science.
Intas Pharmaceuticals completes deal to acquire
Actavis UK & Ireland generics businesses from Teva
Intas Pharmaceuticals Ltd. (“Intas”), through
its wholly owned subsidiary Accord Healthcare
Ltd. (“Accord”), has completed the deal to
acquire Actavis UK Ltd. & Actavis Ireland
Ltd. (“Actavis UK & Ireland”) from Teva
Pharmaceutical Industries Ltd. (“Teva”), for
an enterprise value of £603 million payable
in cash. The transaction is part of the European Commission’s
anti-trust divestiture requirements arising from Teva’s
acquisition of Allergan’s generics business.
Following the completion of the acquisition, Accord
strengthens its footprint in the UK and Ireland retail market to
become a leading player in the industry at European level, while
Intas becomes a top 20 generic player globally. The combination
with Actavis UK Ltd. and Actavis Ireland gives Accord an
exciting opportunity to build on its already
strong position in the market, providing the
company with increased access to UK and Irish
retail and hospital markets. The combination of
these two, high-performing businesses expands
Accord’s UK manufacturing presence, and the
addition of the GMP Barnstaple site that was
included in the acquisition, further demonstrates Accord’s
commitment to UK manufacturing and adds to the recent
significant investment to reinstate a facility in Newcastle. The
Barnstaple plant will become one of Accord’s four UK sites,
ensuring the company has one of the most extensive local
supply chains, providing service to wholesalers, hospitals and
pharmacies across the UK and Ireland, as well as into Europe.
IPUREVIEW FEBRUARY 2017 63